 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 September 2003 | Volume 139 Issue 6 | Pages 476-482
Background: Since most hip fractures are related to osteoporosis, treating accelerated bone loss can be an important strategy to prevent hip fractures. Thiazides have been associated with reduced age-related bone loss by decreasing urinary calcium excretion.
Objective: To examine the association between dose and duration of thiazide diuretic use and the risk for hip fracture and to study the consequences of discontinuing use.
Design: Prospective population-based cohort study.
Setting: The Rotterdam Study.
Participants: 7891 individuals 55 years of age and older.
Measurements: Hip fractures were reported by the general practitioners and verified by trained research assistants. Details of all dispensed drugs were available on a day-to-day basis. Exposure to thiazides was divided into 7 mutually exclusive categories: never use, current use for 1 to 42 days, current use for 43 to 365 days, current use for more than 365 days, discontinuation of use since 1 to 60 days, discontinuation of use since 61 to 120 days, and discontinuation of use since more than 120 days.
Results: 281 hip fractures occurred. Relative to nonuse, current use of thiazides for more than 365 days was statistically significantly associated with a lower risk for hip fracture (hazard ratio, 0.46 [95% CI, 0.21 to 0.96]). There was no clear dose dependency. This lower risk disappeared approximately 4 months after thiazide use was discontinued.
Conclusions: Thiazide diuretics protect against hip fracture, but this protective effect disappears within 4 months after use is discontinued.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From Erasmus MC, Rotterdam, the Netherlands; PHARMO Institute, Utrecht, the Netherlands; and Inspectorate for Health Care, The Hague, the Netherlands.
Acknowledgments: The authors thank the people of the Rotterdam Study for participation and the research physicians and assistants of the Rotterdam Study for data collection.
Grant Support: No external funding was obtained for this study.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Bruno H.Ch. Stricker, MB, PhD, Department of Epidemiology and Biostatistics, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, the Netherlands.
Current Author Addresses: Drs. Schoofs, Hofman, Stijnen, and Stricker: Department of Epidemiology and Biostatistics, Erasmus MC, PO Box 1738, 3000 DR, Rotterdam, the Netherlands.
Drs. van der Klift and Pols: Department of Internal Medicine, Erasmus MC, PO Box 1738, 3000 DR, Rotterdam, the Netherlands.
Dr. de Laet: Department of Public Health, Erasmus MC, PO Box 1738, 3000 DR, Rotterdam, the Netherlands.
Dr. Herings: Prismant, Maliebaan 50, 3581 CS, Utrecht, the Netherlands.
Author Contributions: Conception and design: M.W.C.J. Schoofs, R.M.C. Herings, H.A.P. Pols, B.H.Ch. Stricker.
Analysis and interpretation of the data: M.W.C.J. Schoofs, A. Hofman, T. Stijnen, H.A.P. Pols, B.H.Ch. Stricker.
Drafting of the article: M.W.C.J. Schoofs, R.M.C. Herings, H.A.P. Pols, B.H.Ch. Stricker.
Critical revision of the article for important intellectual content: M. van der Klift, A. Hofman, C.E.D.H. de Laet, R.M.C. Herings, H.A.P. Pols, B.H.Ch. Stricker.
Final approval of the article: M.W.C.J. Schoofs, A. Hofman, H.A.P. Pols, B.H.Ch. Stricker.
Provision of study materials or patients: A. Hofman, H.A.P. Pols.
Statistical expertise: T. Stijnen, B.H.Ch. Stricker.
Obtaining of funding: B.H.Ch. Stricker.
Administrative, technical, or logistic support: H.A.P. Pols, B.H.Ch. Stricker.
Collection and assembly of data: M.W.C.J. Schoofs, M. van der Klift, A. Hofman, C.E.D.H. de Laet, R.M.C. Herings, H.A.P. Pols, B.H.Ch. Stricker. ARTICLE
Thiazide Diuretics and the Risk for Hip Fracture
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M R Law, J K Morris, and N J Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ, May 19, 2009; 338(may19_1): b1665 - b1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shimizu, H. Nakagami, M. K. Osako, R. Hanayama, Y. Kunugiza, T. Kizawa, T. Tomita, H. Yoshikawa, T. Ogihara, and R. Morishita Angiotensin II accelerates osteoporosis by activating osteoclasts FASEB J, July 1, 2008; 22(7): 2465 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hartikainen, E. Lonnroos, and K. Louhivuori Medication as a Risk Factor for Falls: Critical Systematic Review J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2007; 62(10): 1172 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Richards, A. Papaioannou, J. D. Adachi, L. Joseph, H. E. Whitson, J. C. Prior, D. Goltzman, and for the Canadian Multicentre Osteoporosis Study (C Effect of Selective Serotonin Reuptake Inhibitors on the Risk of Fracture Arch Intern Med, January 22, 2007; 167(2): 188 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-X. Yang, J. D. Lewis, S. Epstein, and D. C. Metz Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture JAMA, December 27, 2006; 296(24): 2947 - 2953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Scranton, E. Lawler, M. Young, and J. M. Gaziano Statins and Fracture: Are All Variables Accounted For?--Reply Arch Intern Med, May 8, 2006; 166(9): 1041 - 1042. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Templeton Secondary Osteoporosis J. Am. Acad. Ortho. Surg., November 1, 2005; 13(7): 475 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Law, Y. Sun, S. K. Bhattacharya, V. S. Chhokar, and K. T. Weber Diuretics and Bone Loss in Rats With Aldosteronism J. Am. Coll. Cardiol., July 5, 2005; 46(1): 142 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gamba Molecular Physiology and Pathophysiology of Electroneutral Cation-Chloride Cotransporters Physiol Rev, April 1, 2005; 85(2): 423 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Jordan Good vibrations and strong bones? Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2005; 288(3): R555 - R556. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Schlechte Update in Endocrinology Ann Intern Med, January 18, 2005; 142(2): 126 - 131. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Schlienger, M. E. Kraenzlin, S. S. Jick, and C. R. Meier Use of {beta}-Blockers and Risk of Fractures JAMA, September 15, 2004; 292(11): 1326 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Moreno, C. Tovar-Palacio, P. de los Heros, B. Guzman, N. A. Bobadilla, N. Vazquez, D. Riccardi, E. Poch, and G. Gamba A Single Nucleotide Polymorphism Alters the Activity of the Renal Na+:Cl- Cotransporter and Reveals a Role for Transmembrane Segment 4 in Chloride and Thiazide Affinity J. Biol. Chem., April 16, 2004; 279(16): 16553 - 16560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 From the Library Br. J. Ophthalmol., February 1, 2004; 88(2): 316 - 316. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Malik JournalScan Heart, December 1, 2003; 89(12): 1467 - 1468. [Full Text] [PDF]
|
|
|
|
 |
|
 Thiazide Use Decreases Hip Fracture Risk Journal Watch Women's Health, November 18, 2003; 2003(1118): 2 - 2. [Full Text]
|
|
